|
Gene: PRPF40A |
Gene summary for PRPF40A |
Gene summary. |
Gene information | Species | Human | Gene symbol | PRPF40A | Gene ID | 55660 |
Gene name | pre-mRNA processing factor 40 homolog A | |
Gene Alias | FBP-11 | |
Cytomap | 2q23.3 | |
Gene Type | protein-coding | GO ID | GO:0000375 | UniProtAcc | O75400 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
55660 | PRPF40A | GSM4909285 | Human | Breast | IDC | 2.80e-15 | 4.63e-01 | 0.21 |
55660 | PRPF40A | GSM4909286 | Human | Breast | IDC | 4.69e-06 | 2.44e-02 | 0.1081 |
55660 | PRPF40A | GSM4909293 | Human | Breast | IDC | 6.86e-09 | 2.49e-01 | 0.1581 |
55660 | PRPF40A | GSM4909296 | Human | Breast | IDC | 3.37e-05 | -1.24e-01 | 0.1524 |
55660 | PRPF40A | GSM4909297 | Human | Breast | IDC | 2.66e-07 | -1.38e-01 | 0.1517 |
55660 | PRPF40A | GSM4909311 | Human | Breast | IDC | 3.13e-20 | -2.30e-01 | 0.1534 |
55660 | PRPF40A | GSM4909312 | Human | Breast | IDC | 2.76e-06 | -1.35e-01 | 0.1552 |
55660 | PRPF40A | GSM4909317 | Human | Breast | IDC | 3.34e-14 | 5.43e-01 | 0.1355 |
55660 | PRPF40A | GSM4909318 | Human | Breast | IDC | 1.00e-03 | 5.58e-01 | 0.2031 |
55660 | PRPF40A | GSM4909319 | Human | Breast | IDC | 8.03e-23 | -3.08e-01 | 0.1563 |
55660 | PRPF40A | GSM4909321 | Human | Breast | IDC | 3.63e-08 | -2.03e-01 | 0.1559 |
55660 | PRPF40A | brca2 | Human | Breast | Precancer | 2.22e-02 | 8.95e-02 | -0.024 |
55660 | PRPF40A | M2 | Human | Breast | IDC | 9.27e-04 | 3.55e-01 | 0.21 |
55660 | PRPF40A | NCCBC14 | Human | Breast | DCIS | 7.38e-08 | 1.27e-01 | 0.2021 |
55660 | PRPF40A | NCCBC5 | Human | Breast | DCIS | 8.34e-06 | -9.26e-02 | 0.2046 |
55660 | PRPF40A | P1 | Human | Breast | IDC | 6.62e-08 | 5.53e-02 | 0.1527 |
55660 | PRPF40A | DCIS2 | Human | Breast | DCIS | 4.07e-57 | 4.15e-01 | 0.0085 |
55660 | PRPF40A | HTA11_3410_2000001011 | Human | Colorectum | AD | 9.45e-15 | -5.37e-01 | 0.0155 |
55660 | PRPF40A | HTA11_2487_2000001011 | Human | Colorectum | SER | 1.09e-02 | -3.92e-01 | -0.1808 |
55660 | PRPF40A | HTA11_696_2000001011 | Human | Colorectum | AD | 2.96e-02 | -3.45e-01 | -0.1464 |
Page: 1 2 3 4 5 6 7 8 9 10 11 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00083809 | Breast | Precancer | RNA splicing | 65/1080 | 434/18723 | 1.27e-12 | 2.53e-10 | 65 |
GO:00003759 | Breast | Precancer | RNA splicing, via transesterification reactions | 52/1080 | 324/18723 | 1.74e-11 | 2.22e-09 | 52 |
GO:00003779 | Breast | Precancer | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 51/1080 | 320/18723 | 3.55e-11 | 4.04e-09 | 51 |
GO:00003989 | Breast | Precancer | mRNA splicing, via spliceosome | 51/1080 | 320/18723 | 3.55e-11 | 4.04e-09 | 51 |
GO:00226049 | Breast | Precancer | regulation of cell morphogenesis | 29/1080 | 309/18723 | 6.88e-03 | 4.67e-02 | 29 |
GO:000838014 | Breast | IDC | RNA splicing | 73/1434 | 434/18723 | 1.27e-10 | 1.57e-08 | 73 |
GO:000037514 | Breast | IDC | RNA splicing, via transesterification reactions | 58/1434 | 324/18723 | 9.44e-10 | 9.58e-08 | 58 |
GO:000037714 | Breast | IDC | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 57/1434 | 320/18723 | 1.60e-09 | 1.49e-07 | 57 |
GO:000039814 | Breast | IDC | mRNA splicing, via spliceosome | 57/1434 | 320/18723 | 1.60e-09 | 1.49e-07 | 57 |
GO:000838024 | Breast | DCIS | RNA splicing | 73/1390 | 434/18723 | 3.05e-11 | 5.08e-09 | 73 |
GO:000037524 | Breast | DCIS | RNA splicing, via transesterification reactions | 58/1390 | 324/18723 | 2.89e-10 | 3.34e-08 | 58 |
GO:000037724 | Breast | DCIS | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 57/1390 | 320/18723 | 5.01e-10 | 5.35e-08 | 57 |
GO:000039824 | Breast | DCIS | mRNA splicing, via spliceosome | 57/1390 | 320/18723 | 5.01e-10 | 5.35e-08 | 57 |
GO:0008380 | Colorectum | AD | RNA splicing | 169/3918 | 434/18723 | 3.59e-18 | 2.04e-15 | 169 |
GO:0000377 | Colorectum | AD | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 130/3918 | 320/18723 | 5.88e-16 | 2.16e-13 | 130 |
GO:0000398 | Colorectum | AD | mRNA splicing, via spliceosome | 130/3918 | 320/18723 | 5.88e-16 | 2.16e-13 | 130 |
GO:0000375 | Colorectum | AD | RNA splicing, via transesterification reactions | 131/3918 | 324/18723 | 7.11e-16 | 2.22e-13 | 131 |
GO:0022604 | Colorectum | AD | regulation of cell morphogenesis | 109/3918 | 309/18723 | 3.08e-09 | 2.07e-07 | 109 |
GO:0008360 | Colorectum | AD | regulation of cell shape | 56/3918 | 154/18723 | 7.01e-06 | 1.73e-04 | 56 |
GO:0000910 | Colorectum | AD | cytokinesis | 59/3918 | 173/18723 | 3.74e-05 | 6.75e-04 | 59 |
Page: 1 2 3 4 5 6 7 8 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa030408 | Breast | Precancer | Spliceosome | 39/684 | 217/8465 | 1.44e-06 | 2.27e-05 | 1.74e-05 | 39 |
hsa0304013 | Breast | Precancer | Spliceosome | 39/684 | 217/8465 | 1.44e-06 | 2.27e-05 | 1.74e-05 | 39 |
hsa0304023 | Breast | IDC | Spliceosome | 40/867 | 217/8465 | 1.53e-04 | 1.42e-03 | 1.06e-03 | 40 |
hsa0304033 | Breast | IDC | Spliceosome | 40/867 | 217/8465 | 1.53e-04 | 1.42e-03 | 1.06e-03 | 40 |
hsa0304043 | Breast | DCIS | Spliceosome | 40/846 | 217/8465 | 8.97e-05 | 8.52e-04 | 6.28e-04 | 40 |
hsa0304053 | Breast | DCIS | Spliceosome | 40/846 | 217/8465 | 8.97e-05 | 8.52e-04 | 6.28e-04 | 40 |
hsa03040 | Colorectum | AD | Spliceosome | 73/2092 | 217/8465 | 1.73e-03 | 9.68e-03 | 6.18e-03 | 73 |
hsa030401 | Colorectum | AD | Spliceosome | 73/2092 | 217/8465 | 1.73e-03 | 9.68e-03 | 6.18e-03 | 73 |
hsa030409 | Endometrium | AEH | Spliceosome | 54/1197 | 217/8465 | 1.47e-05 | 1.65e-04 | 1.21e-04 | 54 |
hsa0304014 | Endometrium | AEH | Spliceosome | 54/1197 | 217/8465 | 1.47e-05 | 1.65e-04 | 1.21e-04 | 54 |
hsa0304024 | Endometrium | EEC | Spliceosome | 54/1237 | 217/8465 | 3.78e-05 | 3.88e-04 | 2.89e-04 | 54 |
hsa0304034 | Endometrium | EEC | Spliceosome | 54/1237 | 217/8465 | 3.78e-05 | 3.88e-04 | 2.89e-04 | 54 |
hsa0304018 | Esophagus | HGIN | Spliceosome | 79/1383 | 217/8465 | 3.22e-13 | 7.00e-12 | 5.56e-12 | 79 |
hsa0304019 | Esophagus | HGIN | Spliceosome | 79/1383 | 217/8465 | 3.22e-13 | 7.00e-12 | 5.56e-12 | 79 |
hsa0304027 | Esophagus | ESCC | Spliceosome | 128/4205 | 217/8465 | 3.31e-03 | 8.79e-03 | 4.50e-03 | 128 |
hsa0304037 | Esophagus | ESCC | Spliceosome | 128/4205 | 217/8465 | 3.31e-03 | 8.79e-03 | 4.50e-03 | 128 |
hsa030407 | Liver | Cirrhotic | Spliceosome | 102/2530 | 217/8465 | 5.69e-08 | 9.47e-07 | 5.84e-07 | 102 |
hsa0304012 | Liver | Cirrhotic | Spliceosome | 102/2530 | 217/8465 | 5.69e-08 | 9.47e-07 | 5.84e-07 | 102 |
hsa0304022 | Liver | HCC | Spliceosome | 122/4020 | 217/8465 | 5.55e-03 | 1.60e-02 | 8.91e-03 | 122 |
hsa0304032 | Liver | HCC | Spliceosome | 122/4020 | 217/8465 | 5.55e-03 | 1.60e-02 | 8.91e-03 | 122 |
Page: 1 2 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PRPF40A | SNV | Missense_Mutation | novel | c.722N>G | p.Met241Arg | p.M241R | O75400 | protein_coding | tolerated(0.65) | benign(0.184) | TCGA-A7-A26H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | PD |
PRPF40A | SNV | Missense_Mutation | c.2510G>T | p.Arg837Ile | p.R837I | O75400 | protein_coding | deleterious(0.02) | possibly_damaging(0.503) | TCGA-D8-A1JG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
PRPF40A | SNV | Missense_Mutation | rs765112518 | c.742G>A | p.Glu248Lys | p.E248K | O75400 | protein_coding | tolerated(0.78) | benign(0) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PRPF40A | SNV | Missense_Mutation | c.1098G>C | p.Lys366Asn | p.K366N | O75400 | protein_coding | deleterious(0) | possibly_damaging(0.835) | TCGA-E9-A1N9-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
PRPF40A | SNV | Missense_Mutation | c.2414N>T | p.Ser805Leu | p.S805L | O75400 | protein_coding | deleterious(0) | probably_damaging(0.916) | TCGA-EW-A1OZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Targeted Molecular therapy | trastuzumab | SD | |
PRPF40A | SNV | Missense_Mutation | novel | c.1499G>A | p.Arg500Gln | p.R500Q | O75400 | protein_coding | deleterious(0.03) | probably_damaging(0.992) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
PRPF40A | SNV | Missense_Mutation | c.2422N>A | p.Asp808Asn | p.D808N | O75400 | protein_coding | tolerated(0.07) | benign(0.202) | TCGA-C5-A1BJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
PRPF40A | SNV | Missense_Mutation | c.1618N>A | p.Glu540Lys | p.E540K | O75400 | protein_coding | tolerated(0.46) | possibly_damaging(0.81) | TCGA-EK-A2RN-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
PRPF40A | SNV | Missense_Mutation | novel | c.2203N>A | p.Glu735Lys | p.E735K | O75400 | protein_coding | deleterious(0.01) | probably_damaging(0.981) | TCGA-LP-A4AU-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
PRPF40A | SNV | Missense_Mutation | c.1205G>C | p.Ser402Thr | p.S402T | O75400 | protein_coding | tolerated(0.12) | probably_damaging(0.964) | TCGA-A6-A567-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Unknown | Unknown | PD |
Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |